Could a genetic marker guide future cancer therapies in taiwan?
NCT ID NCT06665776
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This study is measuring how often a specific genetic marker (HLA-A*02:01) and a cancer-related protein (NY-ESO-1) appear in Taiwanese patients with solid tumors like head and neck, liver, lung, breast, and esophageal cancers. By understanding these frequencies, researchers hope to identify which patients might benefit from future targeted immunotherapies. The study involves collecting blood and tumor tissue samples from about 485 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If certain markers are common, this could help design targeted immunotherapies for Taiwanese cancer patients.
- What could go wrong
- This is an observational study only—it does not test any treatment. The findings may not lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Memorial Hospital, Chiayi Branch
Chiayi City, Taiwan, Taiwan
-
National Cheng Kung University Hospital
Tainan, Taiwan, 704, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan, 407219, Taiwan
-
Taipei Medical University Hospital
Taipei, Taiwan, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan, 11217, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a single Protein's mutations predict esophageal cancer outcomes?